IRVINE, Calif., Oct. 16 /PRNewswire-FirstCall/ -- Edwards Lifesciences Corporation , a world leader in products and technologies to treat advanced cardiovascular disease, today announced its schedule of activities for the Cardiovascular Research Foundation’s (CRF) nineteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, from Oct. 20 through 25 in Washington, D.C.
Edwards will also host an analyst luncheon on Wednesday, Oct. 24, at 12:00 p.m. EDT. The featured speakers at the luncheon will be Augusto Pichard, M.D., Professor of Medicine and Director of the Cardiac Catheterization Laboratories, Washington Center Hospital, Washington, D.C., and Alex Powell, M.D., Interventional Radiologist, Baptist Cardiac and Vascular Institute, Miami, Fla.
Dr. Pichard will discuss his experiences with the Edwards SAPIEN transcatheter aortic heart valve and the RetroFlex transfemoral delivery system. He will also provide his perspective on the potential this valve replacement technology has in treating high-risk patients suffering from severe aortic stenosis.
Dr. Powell will discuss the one-year results from the RESILIENT trial, the landmark randomized study of the Edwards LifeStent Self-Expanding Stent for the treatment of peripheral vascular disease in the superficial femoral artery (SFA).
A live webcast of the presentation will be available on the Edwards investor relations website at http://www.edwards.com/InvestorRelations/EventCalendar.htm from 12:30 to 1:30 p.m. EDT. An archived version of the webcast will be available later that day on the Edwards investor relations website in the News and Events section.
In addition to the analyst luncheon, the TCT program will include a number of clinical presentations featuring several of Edwards’ interventional cardiovascular technologies. Among the presentations are (all times EDT):
Representatives from Edwards will also be in the exhibition area at booth 5041 on level two.
About Edwards Lifesciences
Edwards Lifesciences, a leader in advanced cardiovascular disease treatments, is the number-one heart valve company in the world and the global leader in acute hemodynamic monitoring. Headquartered in Irvine, Calif., Edwards focuses on specific cardiovascular disease states including heart valve disease, peripheral vascular disease and critical care technologies. The company’s global brands, which are sold in approximately 100 countries, include Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, LifeStent, PERIMOUNT Magna and Swan-Ganz. Additional company information can be found at http://www.edwards.com.
Edwards, Edwards SAPIEN, MONARC and RetroFlex are trademarks of Edwards Lifesciences Corporation. Edwards Lifesciences, Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz are trademarks of Edwards Lifesciences Corporation and are registered in the United States Patent and Trademark Office. LifeStent is a trademark of Edwards Lifesciences AG and is registered in the United States Patent and Trademark Office.
CONTACT: Media, Sarah Huoh, +1-949-250-5070, or Investors, David K.
Erickson, +1-949-250-6826, both of Edwards Lifesciences Corporation
Web site: http://www.edwards.com/
